분할 루시퍼라아제 분석 시스템을 사용하여 HBx-DDB1 상호 작용의 억제제 식별

Executive Industry Relevance

Targeting the HBx-DDB1 interaction addresses a critical mechanistic bottleneck in hepatitis B virus (HBV) drug discovery, enabling direct intervention at the level of viral protein expression. The split luciferase assay system provides real-time, quantitative readouts for inhibitor screening, supporting predictive confidence in early-stage target validation. This platform strengthens portfolio triage by enabling high-throughput identification of compounds with novel antiviral mechanisms.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables direct interrogation of the HBx-DDB1 protein-protein interaction central to HBV pathogenesis.
• Supports biological de-risking by linking inhibition to restoration of Smc5/6 and suppression of viral transcription.
• Facilitates predictive confidence in target engagement through real-time, live-cell measurement.

Screening & Assay Development

• Delivers a validated, high Z prime assay suitable for high-throughput compound screening.
• Provides robust, quantitative luminescence outputs for reliable compound ranking.
• Enables reproducible, scalable workflows for screening libraries against protein-protein interactions.

Translational & Preclinical Research

• Aligns with disease-relevant mechanisms by targeting viral protein expression from cccDNA.
• Supports continuity from discovery to preclinical validation by linking molecular inhibition to functional outcomes.
• Reduces translational risk by focusing on a mechanistically validated antiviral target.

Pipeline & Workflow Integration

This split luciferase assay system integrates at the early discovery and lead identification stages, bridging target validation and high-throughput screening for HBV and potentially other viral targets.

• Discovery Biology: Provides a platform for hypothesis testing of protein-protein interaction inhibitors in live cells.
• Screening: Offers assay readiness and reproducibility with high signal-to-background and Z prime metrics.
• Analytics: Generates quantitative inhibition data to compare compound efficacy and selectivity.
• Translational Research: Connects molecular inhibition to restoration of host restriction factors and suppression of viral transcription.
• Enterprise Reuse: Adaptable to other protein-protein interaction targets in infectious disease research.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence in target validation and mechanistic de-risking for HBV drug discovery.
• Operational Value: Standardizes and accelerates screening workflows with robust, reproducible outputs.
• Strategic Value: Enables informed go/no-go decisions and capital-efficient advancement of novel antiviral candidates.
• Portfolio Impact: Supports risk-adjusted prioritization of compounds with unique mechanisms of action.

Implementation Considerations

• Requires expertise in protein-protein interaction assays and live-cell luminescence measurements.
• Needs access to cell culture, transfection reagents, and plate-based luminometry infrastructure.
• Demands cross-team standardization of assay setup and data analysis for reproducibility.
• May require optimization of fusion protein constructs for different target pairs.
• Visual protocol demonstration aids reproducibility for complex assay steps.

Biopharma FAQs